61
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Neurofibromatosis type 1 and pneumoconiosis: A case report on a coincidence

ORCID Icon, ORCID Icon & ORCID Icon
Received 25 Oct 2023, Accepted 13 Feb 2024, Published online: 04 Mar 2024

References

  • Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. Int J Mol Sci. 2021;22(11):5850. doi:10.3390/ijms22115850.
  • Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3(1):17004. doi:10.1038/nrdp.2017.4.
  • Ly KI, Blakeley JO. The diagnosis and management of neurofibromatosis type 1. Med Clin North Am. 2019;103(6):1035–1054. doi:10.1016/j.mcna.2019.07.004.
  • Isakson SH, Rizzardi AE, Coutts AW, et al. Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Commun Biol. 2018;1(1):158. doi:10.1038/s42003-018-0163-y.
  • Zamora AC, Collard HR, Wolters PJ, Webb WR, King TE. Neurofibromatosis-associated lung disease: a case series and literature review. Eur Respir J. 2007;29(1):210–214. doi:10.1183/09031936.06.00044006.
  • Qi XM, Luo Y, Song MY, et al. Pneumoconiosis: current status and future prospects. Chin Med J (Engl). 2021;134(8):898–907. doi:10.1097/CM9.0000000000001461.
  • Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506–1513. doi:10.1038/s41436-021-01170-5.
  • Avanesov M, Well L, Laqmani A, et al. Structural alteration of lung parenchyma in patients with NF1: a phenotyping study using multidetector computed tomography (MDCT). Orphanet J Rare Dis. 2021;16(1):29. doi:10.1186/s13023-021-01672-0.
  • Li T, Yang X, Xu H, Liu H. Early ıdentification, accurate diagnosis, and treatment of silicosis. Can Respir J. 2022;2022:3769134. doi:10.1155/2022/3769134.
  • Akira M, Suganuma N. Imaging diagnosis of pneumoconiosis with predominant nodular pattern: HRCT and pathologic findings. Clin Imaging. 2023;97:28–33. doi:10.1016/j.clinimag.2023.02.010.
  • Júnior SFA, Zanetti G, de Melo ASA, et al. Neurofibromatosis type 1: State-of-the-art review with emphasis on pulmonary involvement. Respir Med. 2019;149:9–15. doi:10.1016/j.rmed.2019.01.002.
  • Ueda K, Honda O, Satoh Y, et al. Computed tomography (CT) findings in 88 neurofibromatosis 1 (NF1) patients: prevalence rates and correlations of thoracic findings. Eur J Radiol. 2015;84(6):1191–1195. doi:10.1016/j.ejrad.2015.02.024.
  • Ryu JH, Parambil JG, Mc Grann PS, Aughenbaugh GL. Lack of Evidence for Association between neurofibromatosis and pulmonary fibrosis. Chest. 2005;128(4):2381–2386. doi:10.1378/chest.128.4.2381.
  • Oikonomou A, Vadikolias K, Birbilis T, Bouros D, Prassopoulos P. HRCT findings in the lungs of non-smokers with neurofibromatosis. Eur J Radiol. 2011;80(3):e520–e523. doi:10.1016/j.ejrad.2010.11.03.
  • Patchefsky AS, Atkinson WG, Hoch WS, Gordon G, Lipshitz HI. Interstitial pulmonary fibrosis and von Recklinghausen’s disease. An ultrastructural and immunofluorescent study. Chest. 1973;64(4):459–464. doi:10.1378/chest.64.4.459.
  • Adamcakova J, Mokra D. New insights into pathomechanisms and treatment possibilities for lung silicosis. Int J Mol Sci. 2021;22(8):4162. doi:10.3390/ijms22084162.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.